Research Article

Effectiveness of albumin-bilirubin score in predicting mortality in intensive care patients

Volume: 16 Number: 2 June 30, 2025
TR EN

Effectiveness of albumin-bilirubin score in predicting mortality in intensive care patients

Abstract

Aim: The Albumin-Bilirubin (ALBI) score, originally developed to assess liver function in patients with hepatocellular carcinoma, has recently gained attention as a prognostic marker in critically ill patients. This study aimed to evaluate the effectiveness of the ALBI score in predicting mortality among intensive care unit (ICU) patients. Material and Methods: This retrospective study included 157 adult patients admitted to the ICU diverse clinical conditions, including sepsis, respiratory failure, trauma, acute neurological events, and post-cardiac arrest, between November 2023 and November 2024. Clinical data, laboratory parameters, ALBI, SOFA, and APACHE II scores were assessed at ICU admission. The ALBI score is calculated as follows: (log10 bilirubin [μmol/L] × 0.66) + (albumin [g/L] × −0.085). Results: Among the study participants (mean age: 71.7 ± 18.6 years; 55.4% male), 42.7% had diabetes mellitus, 21.7% chronic kidney disease (CKD), 38.9% chronic obstructive pulmonary disease, 73.9% cardiovascular disease, and 19.7% malignancies. The overall mortality rate was 42.7%. Multivariable Cox regression analysis revealed that CKD (HR: 1.90; 95% CI: 1.07–3.39; p = 0.029), higher ALBI scores (HR: 1.65; 95% CI: 1.03–2.65; p = 0.038) and higher APACHE II scores (HR: 1.04; 95% CI: 1.00–1.08; p = 0.031) were independent predictors of mortality. Conclusion: The ALBI score is an independent predictor of mortality among critically ill patients with heterogeneous clinical conditions in general ICU settings. By integrating hepatic dysfunction, nutritional status, and systemic inflammation, ALBI complements traditional prognostic tools and may enhance clinical decision-making and risk stratification.

Keywords

References

  1. Goncalves-Pereira J, Oliveira A, Vieira T, et al. Critically ill patient mortality by age: long-term follow-up (CIMbA-LT). Ann Intensive Care. 2023;13(1):7.
  2. Otero ML, Menezes RC, Ferreira IBB, et al. Factors Associated with Mortality in Critically Ill Patients Diagnosed with Hospital Acquired Infections. Infect Drug Resist. 2020;13:2811-17.
  3. Oliveira A, Vieira T, Rodrigues A, et al. Critically ill patients with high predicted mortality: Incidence and outcome. Med Intensiva (Engl Ed). 2024;48(2):85-91.
  4. Mehta S and Gill SE. Improving clinical outcomes in sepsis and multiple organ dysfunction through precision medicine. J Thorac Dis. 2019;11(1):21-28.
  5. Chung J, Ahn J, and Ryu JA. Beyond SOFA and APACHE II, Novel Risk Stratification Models Using Readily Available Biomarkers in Critical Care. Diagnostics (Basel). 2025;15(9)
  6. Johnson PJ, Berhane S, Kagebayashi C, et al. Assessment of liver function in patients with hepatocellular carcinoma: a new evidence-based approach-the ALBI grade. J Clin Oncol. 2015;33(6):550-8.
  7. Toyoda H and Johnson PJ. The ALBI score: From liver function in patients with HCC to a general measure of liver function. JHEP Rep. 2022;4(10):100557.
  8. Gou E, Yang Q, Chen J, et al. Association between albumin-bilirubin score and in-hospital mortality in patients with sepsis: Evidence from two large databases. Heliyon. 2024;10(15):e34697.

Details

Primary Language

English

Subjects

Predictive and Prognostic Markers

Journal Section

Research Article

Publication Date

June 30, 2025

Submission Date

June 16, 2025

Acceptance Date

June 30, 2025

Published in Issue

Year 2025 Volume: 16 Number: 2

APA
Kerimoğlu, E., Eyüpoğlu, S., & Uyanik, E. (2025). Effectiveness of albumin-bilirubin score in predicting mortality in intensive care patients. Turkish Journal of Clinics and Laboratory, 16(2), 394-401. https://doi.org/10.18663/tjcl.1720604
AMA
1.Kerimoğlu E, Eyüpoğlu S, Uyanik E. Effectiveness of albumin-bilirubin score in predicting mortality in intensive care patients. TJCL. 2025;16(2):394-401. doi:10.18663/tjcl.1720604
Chicago
Kerimoğlu, Elif, Selin Eyüpoğlu, and Eser Uyanik. 2025. “Effectiveness of Albumin-Bilirubin Score in Predicting Mortality in Intensive Care Patients”. Turkish Journal of Clinics and Laboratory 16 (2): 394-401. https://doi.org/10.18663/tjcl.1720604.
EndNote
Kerimoğlu E, Eyüpoğlu S, Uyanik E (June 1, 2025) Effectiveness of albumin-bilirubin score in predicting mortality in intensive care patients. Turkish Journal of Clinics and Laboratory 16 2 394–401.
IEEE
[1]E. Kerimoğlu, S. Eyüpoğlu, and E. Uyanik, “Effectiveness of albumin-bilirubin score in predicting mortality in intensive care patients”, TJCL, vol. 16, no. 2, pp. 394–401, June 2025, doi: 10.18663/tjcl.1720604.
ISNAD
Kerimoğlu, Elif - Eyüpoğlu, Selin - Uyanik, Eser. “Effectiveness of Albumin-Bilirubin Score in Predicting Mortality in Intensive Care Patients”. Turkish Journal of Clinics and Laboratory 16/2 (June 1, 2025): 394-401. https://doi.org/10.18663/tjcl.1720604.
JAMA
1.Kerimoğlu E, Eyüpoğlu S, Uyanik E. Effectiveness of albumin-bilirubin score in predicting mortality in intensive care patients. TJCL. 2025;16:394–401.
MLA
Kerimoğlu, Elif, et al. “Effectiveness of Albumin-Bilirubin Score in Predicting Mortality in Intensive Care Patients”. Turkish Journal of Clinics and Laboratory, vol. 16, no. 2, June 2025, pp. 394-01, doi:10.18663/tjcl.1720604.
Vancouver
1.Elif Kerimoğlu, Selin Eyüpoğlu, Eser Uyanik. Effectiveness of albumin-bilirubin score in predicting mortality in intensive care patients. TJCL. 2025 Jun. 1;16(2):394-401. doi:10.18663/tjcl.1720604

e-ISSN: 2149-8296

Publication Model: Continuous Publication

Peer Review Model: Double-Blind Peer Review

Publication Language: Turkish and English

Access Model: Open Access

DOI Prefix: (Crossref DOI numaranız)

Publisher: DNT Ortadoğu Publishing Inc.

Journal Abbreviation: Turk J Clin Lab

Indexed in J-Gate

The content of this site is intended for health care professionals. All the published articles are distributed under the terms of

Creative Commons Attribution Licence,

which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.